Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

Papatheodoridi, Μargarita; Hiriart, Jean Baptiste; Lupșor-Platon, Monica; Bronte, F.; Boursier, Jérôme; Elshaarawy, Omar; Marra, Fabio; Thiele, Maja; Markakis, Georgios; Payancé, Audrey; Brodkin, Edgar; Castéra, Laurent; Papatheodoridis, George; Krag, Aleksander; Arena, Umberto; Mueller, Sebastian; Calès, Paul; Calvaruso, V.; Lédinghen, Victor de; Pinzani, Massimo; Tsochatzis, Emmanuel

doi:10.1016/j.jhep.2020.11.050

Cited by 142 publications

(143 citation statements)

References 23 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Consequently, the same diagnostic cut-offs can be used with both probes. A highly accurate cut-off to rule out advanced fibrosis in NAFLD is 8 kPa, while 12-15 kPa rules in advanced fibrosis with good accuracy, if causes of false positive measurements can be excluded [19,32].…”

Section: Ultrasound Elastography and Controlled Attenuation Parametermentioning

confidence: 99%

The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients

Wernberg

Ravnskjær

Lauridsen

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Liver disease due to metabolic dysfunction constitute a worldwide growing health issue. Severe obesity is a particularly strong risk factor for non-alcoholic fatty liver disease, which affects up to 93% of these patients. Current diagnostic markers focus on the detection of advanced fibrosis as the major predictor of liver-related morbidity and mortality. The most accurate diagnostic tools use elastography to measure liver stiffness, with diagnostic accuracies similar in normal-weight and severely obese patients. The effectiveness of elastography tools are however hampered by limitations to equipment and measurement quality in patients with very large abdominal circumference and subcutaneous fat. Blood-based biomarkers are therefore attractive, but those available to date have only moderate diagnostic accuracy. Ongoing technological advances in omics technologies such as genomics, transcriptomics, and proteomics hold great promise for discovery of biomarkers and increased pathophysiological understanding of non-alcoholic liver disease and steatohepatitis. Very recent developments have allowed for single-cell sequencing and cell-type resolution of gene expression and function. In the near future, we will therefore likely see a multitude of breakthrough biomarkers, developed from a deepened understanding of the biological function of individual cell types in the healthy and injured liver.

show abstract

Section: Ultrasound Elastography and Controlled Attenuation Parametermentioning

confidence: 99%

The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients

Wernberg

Ravnskjær

Lauridsen

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…We read with interest the article by Papatheodoridi, et al (1) proposing a change in the cutoffs for excluding and diagnosing compensated advanced chronic liver disease (cACLD). We share with the authors the need for validation of these criteria for ruling in and out cACLD.…”

Section: To the Editormentioning

confidence: 99%

Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?

Genescà

Abraldes

Bosch

2021

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…They propose a dual cut-off of <7 kPa and >12 kPa to optimize the overall predictive performance of TE when assessing the presence or absence of cACLD and with which they were able to correctly classify more than 80% of patients with chronic liver disease. In the gray zone, a formula taking the patient’s age, male gender, ALT/AST/yGT values, platelet counts, and the presence of type 2 diabetes into account was proposed [ 14 ]. Important study observations show that the reliability of the elastographic measurement increases if two consecutive measurements are performed in a time window of 3–6 months.…”

Section: Elastographic Assessment Of Liver Fibrosismentioning

confidence: 99%

“…Note the important disadvantage of the chart—evaluation of the inflammation (NASH) presence and the inflammatory activity degree. Inclusion of proposed formulas reported by Papatheodoridi et al [ 14 ] is recommended.…”

Section: Elastographic Assessment Of Liver Fibrosismentioning

confidence: 99%

Ultrasound Elastography—Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment

Hari

2021

Medicina

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease has become the most common chronic liver disease as well as the most common cause for liver transplantation. With its different methods types, elastography of the liver can be used for non-invasive evaluation of the liver fibrosis and steatosis degree. The article focuses on the description, use, advantages, and limitations of the currently known elastographic techniques. It proposes a simple risk assessment algorithm for the liver fibrosis progress evaluation. The following is an overview of the use of liver and spleen elastography in the detection of clinically relevant portal hypertension. It concludes with research and technological possibilities that could be important to the field in the upcoming years.

show abstract

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

Cited by 142 publications

References 23 publications

The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients

The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients

Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?

Ultrasound Elastography—Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment

Contact Info

Product

Resources

About